Literature DB >> 11222732

Membrane-anchored peptide inhibits human immunodeficiency virus entry.

M Hildinger1, M T Dittmar, P Schult-Dietrich, B Fehse, B S Schnierle, S Thaler, G Stiegler, R Welker, D von Laer.   

Abstract

Peptides derived from the heptad repeats of human immunodeficiency virus (HIV) gp41 envelope glycoprotein, such as T20, can efficiently inhibit HIV type 1 (HIV-1) entry. In this study, replication of HIV-1 was inhibited more than 100-fold in a T-helper cell line transduced with a retrovirus vector expressing membrane-anchored T20 on the cell surface. Inhibition was independent of coreceptor usage.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11222732      PMCID： PMC115933          DOI： 10.1128/JVI.75.6.3038-3042.2001

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  30 in total

1.  High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein.

Authors:  F Grignani; T Kinsella; A Mencarelli; M Valtieri; D Riganelli; F Grignani; L Lanfrancone; C Peschle; G P Nolan; P G Pelicci
Journal:  Cancer Res       Date:  1998-01-01       Impact factor: 12.701

2.  High-titer packaging cells producing recombinant retroviruses resistant to human serum.

Authors:  F L Cosset; Y Takeuchi; J L Battini; R A Weiss; M K Collins
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

3.  Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells.

Authors:  B S Schnierle; J Stitz; V Bosch; F Nocken; H Merget-Millitzer; M Engelstädter; R Kurth; B Groner; K Cichutek
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

4.  Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

Authors:  L T Rimsky; D C Shugars; T J Matthews
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

Review 5.  Gene therapy for AIDS.

Authors:  T Sorg; M Methali
Journal:  Transfus Sci       Date:  1997-06

6.  An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.

Authors:  J Konvalinka; M A Litterst; R Welker; H Kottler; F Rippmann; A M Heuser; H G Kräusslich
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

Authors:  C T Wild; D C Shugars; T K Greenwell; C B McDanal; T J Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

8.  Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA.

Authors:  G Sczakiel; M Pawlita
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1.

Authors:  P Lusso; F Cocchi; C Balotta; P D Markham; A Louie; P Farci; R Pal; R C Gallo; M S Reitz
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

10.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.

Authors:  A Buchacher; R Predl; K Strutzenberger; W Steinfellner; A Trkola; M Purtscher; G Gruber; C Tauer; F Steindl; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-04       Impact factor: 2.205
View more
  47 in total

Review 1.  Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

Authors:  Cecilia Frecha; Camille Lévy; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

2.  Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides.

Authors:  Xi Chen; Lu Lu; Zhi Qi; Hong Lu; Ji Wang; Xiaoxia Yu; Yinghua Chen; Shibo Jiang
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

3.  The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.

Authors:  Antonella Castagna; Priscilla Biswas; Alberto Beretta; Adriano Lazzarin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.

Authors:  Paolo Ingallinella; Elisabetta Bianchi; Neal A Ladwa; Ying-Jie Wang; Renee Hrin; Maria Veneziano; Fabio Bonelli; Thomas J Ketas; John P Moore; Michael D Miller; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

5.  FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cells.

Authors:  Carole Seguin-Devaux; Jean-Marc Plesseria; Charlène Verschueren; Cécile Masquelier; Gilles Iserentant; Marie Fullana; Mihály Józsi; Jacques H M Cohen; Xavier Dervillez
Journal:  Mol Oncol       Date:  2019-09-30       Impact factor: 6.603

Review 6.  Subcellular targeting strategies for drug design and delivery.

Authors:  Lawrence Rajendran; Hans-Joachim Knölker; Kai Simons
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

7.  A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.

Authors:  Xiaoran Tang; Hongliang Jin; Yue Chen; Li Li; Yuanmei Zhu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

8.  Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.

Authors:  Gregory B Melikyan; Marc Egelhofer; Dorothee von Laer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

9.  HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranes.

Authors:  Pedro M Matos; Miguel A R B Castanho; Nuno C Santos
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

10.  Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection.

Authors:  Janine Kimpel; Stephen E Braun; Gang Qiu; Fay Eng Wong; Michelle Conolle; Jörn E Schmitz; Christian Brendel; Laurent M Humeau; Boro Dropulic; John J Rossi; Annemarie Berger; Dorothee von Laer; R Paul Johnson
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.